Pomalidomide plus antibody treatment for untreated lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a three-drug combination (pomalidomide, an anti-CD20 antibody, and prednisone) to treat certain slow-growing B-cell lymphomas that have never been treated before. The goal is to see if this combination works better than standard approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with one of these slow-growing lymphomas: follicular lymphoma, marginal zone lymphoma, indolent mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia
- You have never received chemotherapy or other systemic cancer treatment for your lymphoma
- Your blood counts are adequate (white blood cells >3,000/µL, neutrophils ≥1.5 × 10⁹/L, platelets ≥75 × 10⁹/L, hemoglobin ≥9.0 g/dL)
- Your liver and kidney function are nearly normal (bilirubin ≤2.0 × normal limit, liver enzymes ≤2.5 × normal limit, kidney function clearance >30 mL/min)
- You are in good enough health to tolerate treatment (expected survival ≥3 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—pomalidomide (a pill) and obinutuzumab (an infusion)—for adults whose indolent lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination works better and is safe for this type of lymphoma.
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
This trial tests a combination of three drugs (pomalidomide, rituximab, and an immunotherapy called anti-PD-1) for people with diffuse large B-cell lymphoma that has not responded or has come back after two prior treatments. The goal is to see if this combination can help control the lymphoma.
This Phase 2 trial tests a combination medicine (thiotepa plus pomalidomide) for people whose primary central nervous system lymphoma has come back or did not respond to prior chemotherapy. It may help shrink lymphoma in the brain/spinal fluid and improve disease control.
Hear when a new Indolent Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.